Does Ketorolac Increase the Risk of Hematoma After Reduction Mammoplasty? A Case-control Study. View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2015-2017

ABSTRACT

The investigators hope to answer the question, "does ketorolac increase the risk of hematoma after reduction mammoplasty?" using a case-control study. All patients who developed a hematoma post reduction mammoplasty (cases) at our institution, and match these with women who had an uncomplicated reduction mammoplasty (controls), and then compare frequency of ketorolac exposure between these two groups as the primary outcome. If ketorolac increases the risk of hematoma, one should expect cases to have been exposed to ketorolac more frequently than controls. Based on previously existing literature, the investigators hypothesize that cases and controls will not differ in their ketorolac exposure, that is, ketorolac does not increase the risk of hematoma. Detailed Description The electronic health record databases of St. Joseph's Healthcare Hamilton and Hamilton Health Sciences will be searched, using the coding system, for all cases of reduction mammoplasty with post--operative hematoma as a complication. Only hematomas which required return to the operating room for evacuation will be included (i.e. those treated with observation or needle aspiration will be excluded). Cases are defined as patients suffering a hematoma post reduction mammoplasty will be identified through hospital coding, and matched with controls based on the following criteria: age, body mass index (BMI), pre-existing hypertension, and institution. Controls are defined as patients who had uncomplicated reduction mammoplasty, and will be randomly pulled through retrospective chart review within the same databases, in the same time period (±5 years). All patient data will be de--identified, and all devices containing patient information will remain on hospital grounds, and be encrypted according to our hospital protocols. The following data will be extracted from patient charts: age, date of surgery, body mass index, surgeon, anesthetist, volume of breast tissue removed per breast, comorbidities, platelet count, coagulation profile, ketorolac and opioid use including dose, timing, frequency, duration, and route of administration of both, time to discharge including length of stay if overnight, comorbidities (including smoking status), American Society of Anesthesiology score, and post--operative usage of drains. Matching of cases and controls will be performed by the primary investigator (JB), and at the time of matching, the only visible patient information will be the de-identified patient identification (ID) and the four matching variables (ketorolac exposure was not visible). The frequency of ketorolac exposure between cases and controls will then be reviewed, and the odds ratio (OR) of exposure to ketorolac, with 95% confidence intervals will be calculated. A two by two table will be generated from our data. Since the incidence of hematoma formation after reduction mammoplasty is very low, the odds ratio will closely approximate the relative risk. To evaluate the statistical significance of the ORs, a level of significance of 0.05 will be used. Independent samples t-test will be used to compare continuous demographic data, and Chi-square analysis will be used for ordinal or categorical data between cases and controls. Sample size was calculated using the POWER program, described by Dupont and Plummer in 1990. A sample size of 25 cases matched with 25 controls (total n = 50) was required from the following data: - p0 = 0.32 (approximate rate of ketorolac exposure amongst breast reduction patients from previous literature from Cawthorn et al.) - α = 0.05 (chance of type I error) - P = 0.8 (power) - m = 1 (matching ratio1:1) - Ψ = 3.6 (estimated risk ratio of developing hematoma post breast reduction if exposed to ketorolac, Cawthorn et al.) - Φ = 0.2 (measurable difference) More... »

URL

https://clinicaltrials.gov/show/NCT03280043

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3177", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The investigators hope to answer the question, \"does ketorolac increase the risk of hematoma after reduction mammoplasty?\" using a case-control study. All patients who developed a hematoma post reduction mammoplasty (cases) at our institution, and match these with women who had an uncomplicated reduction mammoplasty (controls), and then compare frequency of ketorolac exposure between these two groups as the primary outcome. If ketorolac increases the risk of hematoma, one should expect cases to have been exposed to ketorolac more frequently than controls. Based on previously existing literature, the investigators hypothesize that cases and controls will not differ in their ketorolac exposure, that is, ketorolac does not increase the risk of hematoma.\n\nDetailed Description\nThe electronic health record databases of St. Joseph's Healthcare Hamilton and Hamilton Health Sciences will be searched, using the coding system, for all cases of reduction mammoplasty with post--operative hematoma as a complication. Only hematomas which required return to the operating room for evacuation will be included (i.e. those treated with observation or needle aspiration will be excluded). Cases are defined as patients suffering a hematoma post reduction mammoplasty will be identified through hospital coding, and matched with controls based on the following criteria: age, body mass index (BMI), pre-existing hypertension, and institution. Controls are defined as patients who had uncomplicated reduction mammoplasty, and will be randomly pulled through retrospective chart review within the same databases, in the same time period (\u00b15 years). All patient data will be de--identified, and all devices containing patient information will remain on hospital grounds, and be encrypted according to our hospital protocols. The following data will be extracted from patient charts: age, date of surgery, body mass index, surgeon, anesthetist, volume of breast tissue removed per breast, comorbidities, platelet count, coagulation profile, ketorolac and opioid use including dose, timing, frequency, duration, and route of administration of both, time to discharge including length of stay if overnight, comorbidities (including smoking status), American Society of Anesthesiology score, and post--operative usage of drains. Matching of cases and controls will be performed by the primary investigator (JB), and at the time of matching, the only visible patient information will be the de-identified patient identification (ID) and the four matching variables (ketorolac exposure was not visible). The frequency of ketorolac exposure between cases and controls will then be reviewed, and the odds ratio (OR) of exposure to ketorolac, with 95% confidence intervals will be calculated. A two by two table will be generated from our data. Since the incidence of hematoma formation after reduction mammoplasty is very low, the odds ratio will closely approximate the relative risk. To evaluate the statistical significance of the ORs, a level of significance of 0.05 will be used. Independent samples t-test will be used to compare continuous demographic data, and Chi-square analysis will be used for ordinal or categorical data between cases and controls. Sample size was calculated using the POWER program, described by Dupont and Plummer in 1990. A sample size of 25 cases matched with 25 controls (total n = 50) was required from the following data: - p0 = 0.32 (approximate rate of ketorolac exposure amongst breast reduction patients from previous literature from Cawthorn et al.) - \u03b1 = 0.05 (chance of type I error) - P = 0.8 (power) - m = 1 (matching ratio1:1) - \u03a8 = 3.6 (estimated risk ratio of developing hematoma post breast reduction if exposed to ketorolac, Cawthorn et al.) - \u03a6 = 0.2 (measurable difference)", 
    "endDate": "2017-08-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT03280043", 
    "keywords": [
      "ketorolac", 
      "reduction mammoplasty", 
      "case-control study", 
      "investigator hope", 
      "risk", 
      "hematoma", 
      "patient", 
      "institution", 
      "MATCH", 
      "woman", 
      "control", 
      "frequency", 
      "primary outcome", 
      "Electronic Health Record", 
      "Hamilton", 
      "health science", 
      "complication", 
      "return", 
      "room", 
      "evacuation", 
      "observation", 
      "aspiration", 
      "hospital", 
      "criterion", 
      "age", 
      "body mass index", 
      "hypertension", 
      "retrospective chart review", 
      "database", 
      "same time period", 
      "patient data", 
      "Equipment and Supply", 
      "patient information", 
      "patient chart", 
      "date", 
      "General Surgery", 
      "surgeon", 
      "volume", 
      "breast tissue", 
      "breast", 
      "comorbidity", 
      "platelet count", 
      "coagulation", 
      "opioid use", 
      "dose", 
      "timing", 
      "duration", 
      "route", 
      "Organization and Administration", 
      "discharge", 
      "smoking status", 
      "American society", 
      "score", 
      "usage", 
      "drain", 
      "primary investigator", 
      "patient identification", 
      "ID", 
      "variable", 
      "odds ratio", 
      "exposure", 
      "confidence interval", 
      "incidence", 
      "statistical significance", 
      "significance", 
      "independent sample", 
      "demographic data", 
      "chi-square analysis", 
      "categorical data", 
      "sample size", 
      "power", 
      "DuPont", 
      "approximates", 
      "reduction", 
      "previous literature", 
      "type I error", 
      "ratio", 
      "measurable difference"
    ], 
    "name": "Does Ketorolac Increase the Risk of Hematoma After Reduction Mammoplasty? A Case-control Study.", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT03280043"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00025.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.416721.7", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.413615.4", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.25073.33", 
        "type": "Organization"
      }
    ], 
    "startDate": "2015-09-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1007/s12630-012-9682-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020056256", 
          "https://doi.org/10.1007/s12630-012-9682-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT03280043"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03280043'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03280043'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03280043'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03280043'


 

This table displays all metadata directly associated to this object as RDF triples.

105 TRIPLES      16 PREDICATES      96 URIs      87 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT03280043 schema:about anzsrc-for:3177
2 schema:description The investigators hope to answer the question, "does ketorolac increase the risk of hematoma after reduction mammoplasty?" using a case-control study. All patients who developed a hematoma post reduction mammoplasty (cases) at our institution, and match these with women who had an uncomplicated reduction mammoplasty (controls), and then compare frequency of ketorolac exposure between these two groups as the primary outcome. If ketorolac increases the risk of hematoma, one should expect cases to have been exposed to ketorolac more frequently than controls. Based on previously existing literature, the investigators hypothesize that cases and controls will not differ in their ketorolac exposure, that is, ketorolac does not increase the risk of hematoma. Detailed Description The electronic health record databases of St. Joseph's Healthcare Hamilton and Hamilton Health Sciences will be searched, using the coding system, for all cases of reduction mammoplasty with post--operative hematoma as a complication. Only hematomas which required return to the operating room for evacuation will be included (i.e. those treated with observation or needle aspiration will be excluded). Cases are defined as patients suffering a hematoma post reduction mammoplasty will be identified through hospital coding, and matched with controls based on the following criteria: age, body mass index (BMI), pre-existing hypertension, and institution. Controls are defined as patients who had uncomplicated reduction mammoplasty, and will be randomly pulled through retrospective chart review within the same databases, in the same time period (±5 years). All patient data will be de--identified, and all devices containing patient information will remain on hospital grounds, and be encrypted according to our hospital protocols. The following data will be extracted from patient charts: age, date of surgery, body mass index, surgeon, anesthetist, volume of breast tissue removed per breast, comorbidities, platelet count, coagulation profile, ketorolac and opioid use including dose, timing, frequency, duration, and route of administration of both, time to discharge including length of stay if overnight, comorbidities (including smoking status), American Society of Anesthesiology score, and post--operative usage of drains. Matching of cases and controls will be performed by the primary investigator (JB), and at the time of matching, the only visible patient information will be the de-identified patient identification (ID) and the four matching variables (ketorolac exposure was not visible). The frequency of ketorolac exposure between cases and controls will then be reviewed, and the odds ratio (OR) of exposure to ketorolac, with 95% confidence intervals will be calculated. A two by two table will be generated from our data. Since the incidence of hematoma formation after reduction mammoplasty is very low, the odds ratio will closely approximate the relative risk. To evaluate the statistical significance of the ORs, a level of significance of 0.05 will be used. Independent samples t-test will be used to compare continuous demographic data, and Chi-square analysis will be used for ordinal or categorical data between cases and controls. Sample size was calculated using the POWER program, described by Dupont and Plummer in 1990. A sample size of 25 cases matched with 25 controls (total n = 50) was required from the following data: - p0 = 0.32 (approximate rate of ketorolac exposure amongst breast reduction patients from previous literature from Cawthorn et al.) - α = 0.05 (chance of type I error) - P = 0.8 (power) - m = 1 (matching ratio1:1) - Ψ = 3.6 (estimated risk ratio of developing hematoma post breast reduction if exposed to ketorolac, Cawthorn et al.) - Φ = 0.2 (measurable difference)
3 schema:endDate 2017-08-01T00:00:00Z
4 schema:keywords American society
5 DuPont
6 Electronic Health Record
7 Equipment and Supply
8 General Surgery
9 Hamilton
10 ID
11 MATCH
12 Organization and Administration
13 age
14 approximates
15 aspiration
16 body mass index
17 breast
18 breast tissue
19 case-control study
20 categorical data
21 chi-square analysis
22 coagulation
23 comorbidity
24 complication
25 confidence interval
26 control
27 criterion
28 database
29 date
30 demographic data
31 discharge
32 dose
33 drain
34 duration
35 evacuation
36 exposure
37 frequency
38 health science
39 hematoma
40 hospital
41 hypertension
42 incidence
43 independent sample
44 institution
45 investigator hope
46 ketorolac
47 measurable difference
48 observation
49 odds ratio
50 opioid use
51 patient
52 patient chart
53 patient data
54 patient identification
55 patient information
56 platelet count
57 power
58 previous literature
59 primary investigator
60 primary outcome
61 ratio
62 reduction
63 reduction mammoplasty
64 retrospective chart review
65 return
66 risk
67 room
68 route
69 same time period
70 sample size
71 score
72 significance
73 smoking status
74 statistical significance
75 surgeon
76 timing
77 type I error
78 usage
79 variable
80 volume
81 woman
82 schema:name Does Ketorolac Increase the Risk of Hematoma After Reduction Mammoplasty? A Case-control Study.
83 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03280043
84 schema:sdDatePublished 2019-03-07T15:27
85 schema:sdLicense https://scigraph.springernature.com/explorer/license/
86 schema:sdPublisher N92586b4f5b6a4bb8a8a1692230fc2c18
87 schema:sponsor https://www.grid.ac/institutes/grid.25073.33
88 https://www.grid.ac/institutes/grid.413615.4
89 https://www.grid.ac/institutes/grid.416721.7
90 schema:startDate 2015-09-01T00:00:00Z
91 schema:subjectOf sg:pub.10.1007/s12630-012-9682-z
92 schema:url https://clinicaltrials.gov/show/NCT03280043
93 sgo:license sg:explorer/license/
94 sgo:sdDataset clinical_trials
95 rdf:type schema:MedicalStudy
96 N92586b4f5b6a4bb8a8a1692230fc2c18 schema:name Springer Nature - SN SciGraph project
97 rdf:type schema:Organization
98 anzsrc-for:3177 schema:inDefinedTermSet anzsrc-for:
99 rdf:type schema:DefinedTerm
100 sg:pub.10.1007/s12630-012-9682-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1020056256
101 https://doi.org/10.1007/s12630-012-9682-z
102 rdf:type schema:CreativeWork
103 https://www.grid.ac/institutes/grid.25073.33 schema:Organization
104 https://www.grid.ac/institutes/grid.413615.4 schema:Organization
105 https://www.grid.ac/institutes/grid.416721.7 schema:Organization
 




Preview window. Press ESC to close (or click here)


...